CDSCO Approval for Combination Products
A combination product can contain a drug and a medical device in one product, or in a single treatment system. This makes its regulatory approval different from that of a standalone drug, or device.
Schedule a Call Back
2,100+ CDSCO medical device assignments since 2018
Clients include Endolite India, Mankind Pharma, Ossur India, ADK Health Care, Credence Prosthetic India, V2U Physio Asia, International Electro Medical Company, Radimage Healthcare India, Istok New Hearing AID, Simpladent Implant Solutions, Starkey Laboratories India, Gentec Medical (12 of 1,100+ served since 2018).
A few more clients we've served in this industryHide the list
- Pharma and healthcare
- Endolite India · Mankind Pharma · Ossur India · ADK Health Care · Credence Prosthetic India · V2U Physio Asia · International Electro Medical Company · Radimage Healthcare India · Istok New Hearing AID · Simpladent Implant Solutions · Starkey Laboratories India · Gentec Medical · Cureesse Pharma · Hygiene Medicus · Nexus Surgical and Medicare
- More clients
- Meditronix Corporation · Nilkamal · Haesi GHL · GHL · Servotech Power Systems · Elektrocraft India · Happy Medicare · Anantaa Gsk Innovations · Cogmac Technologies · Aficionados Tech · Superceuticals · Truevis Technologies · 1008 Digital Health · BDS Services · Evoq Imaging Technologies · Premier Medical Systems and Devices · Riransa · Vitrag Infra Projects · Insta Biotech · Digital Acoustics · Artificial Learning Systems India · Nfilade Security Solutions · Humors Tech · K2O Consulting
Introduction
CDSCO approval for combination products depends on factors such as the product’s components, intended use, mode of action and regulatory status.
Before applying, manufacturers as well as importers need to identify the right regulatory category, and understand which requirements apply. The Central Drugs Standard Control Organization (CDSCO) regulates drugs and medical devices in India under the applicable laws and rules. A product-specific review at the beginning can help avoid filing under the wrong route.
What Are Combination Products Under CDSCO?
A combination product brings together components that may otherwise fall under different regulatory categories.
A common example is a product that combines a medicinal substance with a medical device. The device may deliver the drug, control its delivery/ support the intended treatment.
The term should not be confused with a fixed-dose combination of medicines. A fixed-dose combination contains two, or more active pharmaceutical ingredients in a single dosage form, while a drug-device combination involves a drug and a device working together for the intended use.
For drug-device combination products India, the regulatory position needs to be examined based on the complete product. The manufacturer cannot decide the approval route only by looking at whether the product contains a drug, or a device.
When Is CDSCO Approval Required for Combination Products?
The need for approval depends on the nature of the product and the regulatory status of its components.
For example, the requirements may differ where an already approved drug is used with a medical device compared with a product involving a new drug or a new intended use.
Before starting the application, the manufacturer should establish:
- What components are present in the product?
- What is the intended use?
- What does each component do?
- Which component provides the main therapeutic effect?
- Is the drug already approved in India?
- What is the regulatory status of the device?
- Does the proposed product involve a new indication or claim?
- What safety, quality, testing or clinical information is available?
These specifics aid in identifying the relevant regulatory path.
Additionally, a producer should refrain from interpreting CDSCO registration as a uniform requirement that is applicable to all combination products. The product and its relevant category must be compared to the actual regulatory need.
How Are Combination Products Classified in India?
Combination product classification in India is an important part of the regulatory assessment.
For a device component, the Medical Devices Rules, 2017 provide a risk-based classification system. Medical devices are placed into different classes based on the risk associated with them, and the applicable requirements can vary accordingly.
It is necessary to evaluate the drug component independently. Requirements under the New Drugs and Clinical Trials Rules, 2019 may be applicable if it is classified as a new drug.
Therefore, before determining how the product will be regulated, the manufacturer should evaluate the entire product. Even though a product looks similar to another combination product, its composition, intended application, or mechanism of action may differ, resulting in different requirements.
Getting the classification wrong at the beginning can affect the rest of the application. It may change the documents required, testing, clinical evidence and the authority or route involved.
CDSCO Approval Process for Combination Products
The CDSCO approval process for combination products starts with understanding the product rather than immediately preparing an application.
- Review the Product: Prepare a complete product description covering the drug, and device components, composition, intended use, and mode of action.
The proposed claims should also be clear. The claims made on the product label should match the evidence available to support them.
- Identify the Applicable Regulatory Route: Once the product has been reviewed, determine which regulatory provisions apply.
Medical device requirements are covered under the Medical Devices Rules, 2017. Where the product involves a new drug, the New Drugs and Clinical Trials Rules, 2019 may also need to be considered.
This step is particularly important for combination products because the drug and device components may raise different regulatory requirements.
- Review Testing and Evidence: The type of evidence required depends on the product.
Depending on the case, the manufacturer may need quality information, technical data, testing reports, stability information or clinical data. The evidence should relate to the actual product being submitted and its proposed use.
If the product involves a new drug or requires clinical evaluation, additional requirements may apply under the relevant regulatory framework.
- Prepare the Application: After the regulatory route is established, prepare the relevant application and supporting documents.
Product details should remain consistent throughout the submission. The composition, intended use, manufacturing information, specifications, testing data and labelling should not contradict each other.
For businesses already dealing with CDSCO registration for other regulated products, it is still important to assess a combination product separately rather than copying the documentation or approach used for another product.
Respond to Regulatory Queries: CDSCO may ask for additional information or clarification during the review.
The response should address the specific point raised and provide supporting information where required. If the query relates to classification, testing or clinical evidence, the response should deal with that issue directly.
Documents Required for CDSCO Approval
There is no single document list that works for every combination product. The requirements depend on the product and the regulatory route.
Documents may include:
- Product description and intended use
- Details of the drug and device components
- Composition and specifications
- Manufacturing details
- Quality and testing information
- Stability data, where applicable
- Device classification details
- Clinical or performance data, where required
- Labelling and packaging information
- Risk-related documents
- Manufacturer and manufacturing-site details
- Existing licences or approvals, where applicable
The manufacturer should first establish the regulatory category and then prepare the documents for that route. This reduces the chance of submitting information that does not address the actual regulatory requirements.
Regulatory Requirements for Combination Products in India
The combination product regulatory requirements in India depend on the components and the intended use of the finished product.
For the device component, the Medical Devices Rules, 2017 cover areas such as classification, manufacturing and import licensing. The applicable requirements vary according to the device and its classification.
For the drug component, the relevant provisions under India's drug regulatory framework need to be checked. Where the product falls within the new drug framework, the New Drugs and Clinical Trials Rules, 2019 may apply.
Manufacturers should also keep drug-device combinations separate from fixed-dose combinations. They are not the same regulatory category, even though both involve more than one component.
The same point applies when a business is considering CDSCO registration. Registration or approval requirements should be decided after checking the actual product rather than assuming that all products containing multiple components follow one process.
Also Read: CDSCO Rules for Software as a Medical Device (SaMD) in India 2026
Common Challenges in Combination Product Approval
A few problems can make the approval process harder than it needs to be.
- Wrong Classification: If the product is placed in the wrong category, the application may be prepared around the wrong requirements.
- Incomplete Technical Information: Missing specifications, testing data or manufacturing details can lead to questions during review.
- Unsupported Claims: The claims made for the product should have suitable evidence behind them. A claim that goes beyond the submitted evidence can create regulatory concerns.
- Conflicting Product Details: The product description, technical documents, labelling and application should contain matching information.
- Confusion between Drug and Device Requirements: A combination product may involve requirements from more than one regulatory area. Treating it only as a drug or only as a device can leave important requirements unaddressed.
How a CDSCO Approval Consultant Can Help
A manufacturer may find the approval process difficult when the product involves both drug and medical device requirements. A CDSCO approval consultant India can help assess the product before the application is prepared.
A combination product regulatory consultant India can review the product, help identify the applicable regulatory route and check whether the proposed documents support the intended use and claims.
Businesses looking for CDSCO approval services India can also take support with regulatory assessment, documentation and application-related work. For products that need specialised assistance, combination product approval services India can cover the regulatory work linked to the particular product.
CDSCO Consultant support can be useful before filing as well as during the review stage. It gives the business someone to review the application for gaps, inconsistencies and regulatory issues before they become larger problems.
Planning to apply for CDSCO approval for a combination product? Book a free consultation with our experts to discuss your product, regulatory route and documentation requirements.
Conclusion
CDSCO combination product approval starts with identifying the product correctly. The components, intended use, mode of action, classification and supporting evidence all have a role in deciding the applicable regulatory route.
Manufacturers and importers should not use the same approval approach for every combination product. A drug-device product, a new drug and a fixed-dose combination can have different regulatory requirements.
Getting the regulatory position checked before preparing the application can save time and reduce avoidable corrections later. Businesses that need CDSCO regulatory compliance services can take professional support for product assessment, documentation, application preparation and regulatory queries.
About the Author
Parul Bohral
Legal Content WriterParul Bohral, a BALLB graduate and experienced legal researcher and content writer with expertise in various legal areas, including corporate law and intellectual property. I have gained valuable experience in esteemed legal environments, where I have strengthened my research skills, allowing me to approach legal writing with precision and depth.
As a legal content writer, I am committed to delivering work that not only informs but also engages readers. By staying informed about the latest trends in content marketing and regulatory developments, I ensure that my writing remains sophisticated and meets industry standards. My dedication to thorough research enables me to craft content that is both insightful and impactful.
Related articles
CDSCO MD-7 Endorsement for Medical Devices: A Practical Guide for Manufacturers
2026-10-23
CDSCO Export NOC for r-DNA Products: Who Needs It?
2026-10-21
CDSCO Registration: A Simple Guide to Getting Your License in India 2026
2026-10-21
Importing Cosmetic Gift Sets into India? CDSCO, LMPC & Labelling Checklist
2026-10-14
CDSCO Medical Device Registration Consultant
2026-09-23
CDSCO Registration for Lab Equipment and Diagnostic Devices
2026-09-22